121 related articles for article (PubMed ID: 16631730)
1. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
[TBL] [Abstract][Full Text] [Related]
2. An orally active, primate selective antagonist of LFA-1 inhibits delayed-type hypersensitivity in a humanized-mouse model.
Panzenbeck MJ; Jeanfavre DD; Kelly TA; Lemieux R; Nabozny G; Reilly PL; Desai S
Eur J Pharmacol; 2006 Mar; 534(1-3):233-40. PubMed ID: 16487962
[TBL] [Abstract][Full Text] [Related]
3. Identification of a potent and selective noncovalent cathepsin S inhibitor.
Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
[TBL] [Abstract][Full Text] [Related]
4. Advances in cathepsin S inhibitor design.
Link JO; Zipfel S
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):471-82. PubMed ID: 16889230
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity.
Baugh M; Black D; Westwood P; Kinghorn E; McGregor K; Bruin J; Hamilton W; Dempster M; Claxton C; Cai J; Bennett J; Long C; McKinnon H; Vink P; den Hoed L; Gorecka M; Vora K; Grant E; Percival MD; Boots AM; van Lierop MJ
J Autoimmun; 2011 May; 36(3-4):201-9. PubMed ID: 21439785
[TBL] [Abstract][Full Text] [Related]
6. S-Adenosyl-L-homocysteine hydrolase inhibitor mediates immunosuppressive effects in vivo: suppression of delayed type hypersensitivity ear swelling and peptidoglycan polysaccharide-induced arthritis.
Saso Y; Conner EM; Teegarden BR; Yuan CS
J Pharmacol Exp Ther; 2001 Jan; 296(1):106-12. PubMed ID: 11123369
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin S inhibitors as novel immunomodulators.
Thurmond RL; Sun S; Karlsson L; Edwards JP
Curr Opin Investig Drugs; 2005 May; 6(5):473-82. PubMed ID: 15912960
[TBL] [Abstract][Full Text] [Related]
8. Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells.
Reich M; Lesner A; Legowska A; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Mol Immunol; 2009 Sep; 46(15):2994-9. PubMed ID: 19615749
[TBL] [Abstract][Full Text] [Related]
9. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model.
Jung EJ; Hur M; Kim YL; Lee GH; Kim J; Kim I; Lee M; Han HK; Kim MS; Hwang S; Kim S; Woo AM; Yoon Y; Park HJ; Won J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1005-13. PubMed ID: 19741152
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2.
Buntinx M; Hermans B; Goossens J; Moechars D; Gilissen RA; Doyon J; Boeckx S; Coesemans E; Van Lommen G; Van Wauwe JP
J Pharmacol Exp Ther; 2008 Oct; 327(1):1-9. PubMed ID: 18599682
[TBL] [Abstract][Full Text] [Related]
11. Role of MHC class II expressing CD4+ T cells in proteolipid protein(91-110)-induced EAE in HLA-DR3 transgenic mice.
Mangalam A; Rodriguez M; David C
Eur J Immunol; 2006 Dec; 36(12):3356-70. PubMed ID: 17125142
[TBL] [Abstract][Full Text] [Related]
12. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
13. Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells.
Han S; Kim K; Song Y; Kim H; Kwon J; Lee YH; Lee CK; Lee SJ; Ha N; Kim K
Arch Pharm Res; 2008 Mar; 31(3):370-6. PubMed ID: 18409052
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.
Tully DC; Liu H; Alper PB; Chatterjee AK; Epple R; Roberts MJ; Williams JA; Nguyen KT; Woodmansee DH; Tumanut C; Li J; Spraggon G; Chang J; Tuntland T; Harris JL; Karanewsky DS
Bioorg Med Chem Lett; 2006 Apr; 16(7):1975-80. PubMed ID: 16446091
[TBL] [Abstract][Full Text] [Related]
15. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
16. Administration of anti-type II collagen antibody sustains footpad swelling of mice caused by a delayed-type hypersensitivity reaction and induces severe arthritis.
Tanaka D; Kagari T; Doi H; Shimozato T
Clin Exp Immunol; 2007 May; 148(2):360-7. PubMed ID: 17335554
[TBL] [Abstract][Full Text] [Related]
17. Dependency of the trans vivo delayed type hypersensitivity response on the action of regulatory T cells: implications for monitoring transplant tolerance.
Warnecke G; Chapman SJ; Bushell A; Hernandez-Fuentes M; Wood KJ
Transplantation; 2007 Aug; 84(3):392-9. PubMed ID: 17700166
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin S activity regulates antigen presentation and immunity.
Riese RJ; Mitchell RN; Villadangos JA; Shi GP; Palmer JT; Karp ER; De Sanctis GT; Ploegh HL; Chapman HA
J Clin Invest; 1998 Jun; 101(11):2351-63. PubMed ID: 9616206
[TBL] [Abstract][Full Text] [Related]
19. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
Hale C; Véniant M; Wang Z; Chen M; McCormick J; Cupples R; Hickman D; Min X; Sudom A; Xu H; Matsumoto G; Fotsch C; St Jean DJ; Wang M
Chem Biol Drug Des; 2008 Jan; 71(1):36-44. PubMed ID: 18069989
[TBL] [Abstract][Full Text] [Related]
20. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
